Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
572 people get PSDV articles and Market Currents by email alert.
Get email alerts on PSDV »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
3 Dirt Cheap Drug Companies About To Make A ComebackLouis Dematteis • Tue, Nov 6, 2012 -
-
-
-
-
-
-
-
-
-
7 Undervalued Stocks Exhibiting The Golden CrossKapitall • Tue, Sep 13, 2011 -
-
-
-
-
pSivida's CEO Discusses F1Q13 Results - Earnings Call TranscriptThu, Nov 8, 2012 • 1 Comment
-
pSivida's CEO Discusses F4Q2012 Results - Earnings Call TranscriptMon, Sep 24, 2012 • 2 Comments
-
Psivida Ltd. F2Q10 (Qtr End 12/31/09) Earnings Call TranscriptThu, Feb 11, 2010
-
Business Wire (May 29, 2013)
-
Business Wire (May 13, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 10, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 22, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 30, 2013)
-
Business Wire (Jan 17, 2013)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 1, 2012)
PSDV vs. ETF Alternatives
Company Description
Currently, there's no company description for PSDV.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, June 14, 2:36 PM Shares of pSivida Corp (PSDV +0.9%) gain after the UK's National Institute for Health and Care Excellence issued a draft guidance recommending Iluvien to treat pseudophakic patients with chronic diabetic macular edema considered insufficiently responsive to available therapies, concluding that it's clinically effective in treating vision impairment. Comment! [Healthcare, On the Move]
- Monday, May 13, 4:13 PM pSivida (PSDV): FQ3 EPS of -$0.12 beats by $0.01. Revenue of $513K misses by $137K. Shares +3.8% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Monday, April 29, 3:35 PM pSivida (PSDV +5%) gains today after its licensee Alimera Sciences (ALIM -3.2%) says Iluvien, its treatment for chronic diabetic macular edema, is now available in the UK for treatment of private pay and privately insured patients. Comment! [Healthcare, On the Move, Global & FX]
- Thursday, April 4, 9:12 AM pSivida (PSDV) +12.8% premarket after saying it signed a funded technology evaluation agreement with a leading global pharmaceutical company, which will evaluate PSDV's proprietary Durasert and Tethadur technologies for the unnamed company's select products in ophthalmology. Comment! [Healthcare, On the Move]
-
Thursday, April 4, 9:10 AM
Premarket gainers: CBMX +20%. PSDV +13%. NAVB +10%. ALU +9%. ARIA +6%.
Comment! [On the Move] -
Friday, February 22, 12:53 PM
Midday top 10 gainers: WBMD +25%. EDAP +24%. PSDV +24%. ARUN +22%. BLOX +17%. SSTK +16%. FIRE +15%. B +15%. AVG +12%. RKUS +12%.
Midday top 10 losers: ETRM -20%. MMSI -19%. WIFI -18%. FRO -14%. NVGN -12%. CBMX -12%. VOLC -11%. GMXR -16%. RCKY -11%. REED -11%. Comment! [On the Move] - Wednesday, February 6, 7:06 PM pSivida (PSDV): FQ2 EPS of -$0.11 beats by $0.02. Revenue of $585K misses by $15K. Shares -5.8% AH. (PR) 1 Comment [Earnings, Breaking News, Healthcare, On the Move]
-
Friday, February 1, 12:45 PM
Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move] -
Wednesday, December 19, 2012, 12:45 PM
Midday top 10 gainers: AMPL +119%. DYNT +64%. EDAP +25%. ALTE +24%. STP +16%. PTNR +13%. LDK +12%. GBR +19%. CSUN +12%. ELTK +12%.
Midday top 10 Losers: ONTY -54%. CMGE -21%. PLXT -18%. NICK -15%. DLB -12%. PNTR -11%. PSDV -10%. EGLE -10%. CCUR -10%. PTEK -10%. Comment! [On the Move] - Friday, November 9, 2012, 12:41 PM pSivida (PSDV +3.5%) gains in spite of a mixed FQ1 report late yesterday. What's driving the move is its announcement that it's received FDA clearance to proceed on two pivotal Phase III clinical trials of its lead development product, an injectable micro-insert for posterior uveitis. The trials, scheduled to begin next year, will form the basis for a future NDA submission. (PR) 1 Comment [Healthcare, Earnings, On the Move]
- Thursday, August 2, 2012, 1:08 PM Shares of pSivida (PSDV -12%) slide after it says it's entered into a securities purchase agreement with institutional investors to raise approximately $5.36M in a direct offering. The company plans to sell, in units, around 2.5M shares of common stock and warrants to purchase 624K shares of its common stock, at a price of $2.15 per unit. Comment! [Healthcare, On the Move]
- Monday, July 30, 2012, 10:24 AM pSivida (PSDV +4.75%) signs a funded agreement in which a "leading global biopharmaceutical company" will assess pSivida's Tethadur technology in the field of ophthalmology. The deal is pSivida's first commercial agreement for Tethadur, which is used for delivering proteins and antibodies. (PR) Comment! [Healthcare, On the Move]
-
Thursday, July 26, 2012, 9:12 AM
Premarket gainers: GENE +33%. PSDV +24%. IBIO +21%. S +18%. WDC +17%. AKAM +16%. PCS +14%. TEX +13%. FTNT +13%. STX +11%. WFM +11%. GNC +8%. UN +7%. CROX +7%. BBVA +7%. PHM +7%. SVU +6%. SAN +6%. PSTI +6%. EQIX +6%. ABB +6%. IOC +6%. AEM +6%. FTE +6%. MRVL +6%. NOK +5%. OVTI +5%.
Losers: ZNGA -40%. NG -29%. STRA -17%. GLUU -8%. IPG -6%. ESI -7%. GRPN -6%. FB -6%. ALU -6%. STB -6%. ABX -5%. LVS -5%. 1 Comment [On the Move] - Thursday, July 19, 2012, 10:27 AM pSivida (PSDV) rockets 41% after the FDA says it can skip Phase I and Phase II trials for an eye insert treatment and go straight to Phase III. The product injects a drug into the back of the eye to treat posterior uveitis, an inflammatory disease that is the third-biggest cause of blindness in the U.S. (PR) Comment! [On the Move, Healthcare]
- Monday, February 27, 2012, 2:01 PM Microcaps Alimera Sciences (ALIM +32.1%) and pSivida (PSDV +21.8%) soar off of speculation that the EU will grant approval for eye disease drug Iluvien. 1 Comment [Healthcare, On the Move]
- Friday, November 11, 2011, 1:39 PM Shares of Alimera Sciences (ALIM -72%) are crushed after the FDA fails to approve its Iluvien drug for the treatment of diabetic macular edema, stating that the risks of adverse reactions were "significant." Alimera will need to conduct two additional clinical trials to demonstrate that the product is safe and effective. Shares of Iluvien licensee pSivida (PSDV -54%) also sink. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
Scott Matusow
Listen to pSivida's (NASDAQ:PSDV) Q4 and fiscal year 2012 results today at 4:30 p.m. ET on my show @ http://bit.ly/xP8ArD - View all 1 replies
-
FredChen23: scott - did you end up listening to the CC? if so, what'd you think?
-
- View all 2 replies
-
DAG1996: don't know what the price was when u wrote this but i too am wondering if it's still worth buying and at what entry. -
DAG1996: dilution is to be expected but the UK news is concerning since it implies US approval is unlikely. wish there was more coverage/info.
-
Joe Springer
Alfred is the Mann! $MNKD $AMRN $MNOV $PCRX $PPHM $PSDV $SVNT #biotech #pharma #stocks #finance #speculation http://seekingalpha.com/a/h4r3 - View all 0 replies
-
- View all 20 replies
-
johnjail: they have good partnership, pfizer, baush e lomb and http://bit.ly/O8Ltfg . surely UK news are bad as regards also US approvals
-
-
Scott Matusow
$PSDV Announces Germany Grants ILUVIEN Marketing Authorization for the Treatment of Chronic D-Macular Edema @ http://yhoo.it/MIhtcJ - View all 2 replies
-
-
rseiter: This a wild one...caught the last wave, got in at 2.45 and out at 3.00 in a matter of days
-
Scott Matusow
$PSDV has good news this am.. I maintain that one is one of the best LONG TERM small cap investments around, Top management = execution - View all 6 replies
-
-
lilvj83: i bought this at 3.10 yesterday..whats your thoughts? I am afraid losing money
-
- View all 5 replies
-
RyRy: I don't understand your interest in this stock. there is no volume. ??
-
StockMatusow: because its a well run company with honest and smart management.
-
Scott Matusow
on $PSDV, remember, because warrants expire unexercised at 7.98, those holders have shorted to protect downside - View all 0 replies
-
- View all 2 replies
-
-
StockMatusow: they have more now? i was not aware, my bad.. good little company, give them time, I will bet they execute, bought family account 10,000 LT
LATEST REPLIES
-
Scott Matusow
Listen to pSivida's (NASDAQ:PSDV) Q4 and fiscal year 2012 results today at 4:30 p.m. ET on my show @ http://bit.ly/xP8ArD - View all 1 replies
-
FredChen23: scott - did you end up listening to the CC? if so, what'd you think?
-
- View all 2 replies
-
DAG1996: don't know what the price was when u wrote this but i too am wondering if it's still worth buying and at what entry.
-
DAG1996: dilution is to be expected but the UK news is concerning since it implies US approval is unlikely. wish there was more coverage/info.
-
- View all 20 replies
-
johnjail: they have good partnership, pfizer, baush e lomb and http://bit.ly/O8Ltfg . surely UK news are bad as regards also US approvals
-
-
Scott Matusow
$PSDV Announces Germany Grants ILUVIEN Marketing Authorization for the Treatment of Chronic D-Macular Edema @ http://yhoo.it/MIhtcJ - View all 2 replies
-
-
rseiter: This a wild one...caught the last wave, got in at 2.45 and out at 3.00 in a matter of days
-
- View all 2 replies
-
-
StockMatusow: they have more now? i was not aware, my bad.. good little company, give them time, I will bet they execute, bought family account 10,000 LT
-
Scott Matusow
$PSDV has good news this am.. I maintain that one is one of the best LONG TERM small cap investments around, Top management = execution - View all 6 replies
-
-
lilvj83: i bought this at 3.10 yesterday..whats your thoughts? I am afraid losing money
-
- View all 5 replies
-
RyRy: I don't understand your interest in this stock. there is no volume. ??
-
StockMatusow: because its a well run company with honest and smart management.
-
- View all 10 replies
-
onehardroll: Phemale60, it's still going down......when will we know if it's approved or not? -
-
Scott Matusow
Something might be up with $PSDV besides the relation to $ALIM, I know they are working on things, and the time is right for news - View all 7 replies
-
counsel0857: Personally I think ATRS is doing great. If I hadn't gone all-in in OMPI I would load the boat on ATRS. A "down" day like this is expected!
-
-
- View all 3 replies
-
breaka40: how did we miss supn?? I didn't see it on the fda sites or anything..
-
-
Scott Matusow
$PSDV looks based, should begin to move up slowly, I think more news might be coming there. - View all 6 replies
-
-
-
Scott Matusow
I know I keep talking about $PSDV, and I don't own any because of money in $ATRS, but its the most undervalued co in the sector. - View all 7 replies
-
-
-
Scott Matusow
kind of interesting people cant see an obvious buy-out in my opinion coming with $PSDV - View all 16 replies
-
cornerback2006: Sorry boss, Moved convo to your inbox..Check your mail And no, not waiting on money, I am def long this co -
cornerback2006: So many other catalysts happening these last few days of month, sensory overload! Plus, May is only few days away :-)
-
Scott Matusow
Looks like its possible $PSDV hits 3 bucks a share today. Investors I think can figure that one out :) - View all 14 replies
-
-
-
Scott Matusow
$ACHN $PSDV could be on move today up. ACHN oversold reaction, In my opinion nice entry, PSDV under accumulation, buy out candidate. - View all 1 replies
-
cornerback2006: I bought in on ACHN, hoping they announce good Phase II results b/n now and Sunday, especially w/ the knee-jerk reaction yesterday...